Cognition Therapeutics Expands Clinical Expertise on Medical Advisory Board with Addition of Drs. Mary Sano and Philip Scheltens
April 05, 2019 08:02 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, April 05, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Elects Lisa Ricciardi to its Board of Directors
March 26, 2019 09:51 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, March 26, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Receives European Patent Covering its Alzheimer's Disease Candidate, Elayta™
February 21, 2019 08:03 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease
November 27, 2018 08:03 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative...
Cognition Therapeutics Initiates Patient Dosing in Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer's Disease
November 08, 2018 08:03 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other...
Cognition Therapeutics Presents Additional Elayta™ Clinical Results during Alzheimer's Association International Conference (AAIC) Symposium Session
July 23, 2018 14:19 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, July 23, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurodegenerative disorders, today...
Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer's Disease
June 18, 2018 08:03 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, June 18, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurocognitive disorders, today...
Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of Elayta™ to Expand Understanding of Synaptoprotective Mechanism of Action
May 22, 2018 08:02 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, May 22, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting
March 06, 2018 14:04 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, March 06, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of...
India Globalization's Hyalolex Shows Promise in Treating Patients with Alzheimer's Disease -- CFN Media
February 08, 2018 08:30 ET
|
CFN Media
Seattle, WA, Feb. 08, 2018 (GLOBE NEWSWIRE) -- CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article...